Видео ютуба по тегу Medicines: Efgartigimod

Efficacy and Safety of Efgartigimod to Treat Myasthenia Gravis
Efficacy and Safety of Efgartigimod to Treat Myasthenia Gravis
Exploring the potential of efgartigimod for individualized therapy in myasthenia gravis
Exploring the potential of efgartigimod for individualized therapy in myasthenia gravis
Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP
Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP
Results on Efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
Results on Efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+
ADAPT analysis: efgartigimod for generalized myasthenia gravis
ADAPT analysis: efgartigimod for generalized myasthenia gravis
Phase II study of efgartigimod in pemphigus vulgaris and foliaceus, M. Goebeler et al
Phase II study of efgartigimod in pemphigus vulgaris and foliaceus, M. Goebeler et al
ASH Highlights: Efgartigimod Safe and Effective in Treating Immune Thrombocytopenia (ITP)
ASH Highlights: Efgartigimod Safe and Effective in Treating Immune Thrombocytopenia (ITP)
Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia Gravis
Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia Gravis
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis
Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis
FDA Approves VYVGART (efgartigimod) for Myasthenia Gravis
FDA Approves VYVGART (efgartigimod) for Myasthenia Gravis
ADVANCE IV results: efficacy and safety of intravenous efgartigimod in adults with primary ITP
ADVANCE IV results: efficacy and safety of intravenous efgartigimod in adults with primary ITP
The current treatment landscape for myasthenia gravis
The current treatment landscape for myasthenia gravis
ASH 2022: Efficacy & Safety of iv Efgartigimod in Adults with Primary Immune Thrombocytopenia: ...
ASH 2022: Efficacy & Safety of iv Efgartigimod in Adults with Primary Immune Thrombocytopenia: ...
Fostamatinib and efgartigimod: novel agents in the treatment of ITP
Fostamatinib and efgartigimod: novel agents in the treatment of ITP
A closer look at Vyvgart (Efgartigimod) for Myasthenia Gravis
A closer look at Vyvgart (Efgartigimod) for Myasthenia Gravis
Efgartigimod Was Well-Tolerated in Patients with Generalized Myasthenia Gravis
Efgartigimod Was Well-Tolerated in Patients with Generalized Myasthenia Gravis